{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:21:19Z","timestamp":1772756479421,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,12,31]],"date-time":"2013-12-31T00:00:00Z","timestamp":1388448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s13277-013-1531-3","type":"journal-article","created":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T22:13:58Z","timestamp":1388441638000},"page":"4057-4066","source":"Crossref","is-referenced-by-count":97,"title":["Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients"],"prefix":"10.1007","volume":"35","author":[{"given":"Ana L.","family":"Teixeira","sequence":"first","affiliation":[]},{"given":"Marta","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Silva","sequence":"additional","affiliation":[]},{"given":"M\u00f3nica","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Francisca","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Juliana I.","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Joaquina","family":"Maur\u00edcio","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Lobo","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,12,31]]},"reference":[{"issue":"2","key":"1531_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"S10","key":"1531_CR2","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/cncr.24226","volume":"115","author":"RM Bukowski","year":"2009","unstructured":"Bukowski RM. Prognostic factors for survival in metastatic renal cell carcinoma. Cancer. 2009;115(S10):2273\u201381.","journal-title":"Cancer"},{"issue":"2 Pt 2","key":"1531_CR3","doi-asserted-by":"crossref","first-page":"671s","DOI":"10.1158\/1078-0432.CCR-06-1870","volume":"13","author":"WM Linehan","year":"2007","unstructured":"Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13(2 Pt 2):671s\u20139.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1531_CR4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1758834009358417","volume":"2","author":"C Sahi","year":"2010","unstructured":"Sahi C, Knox JJ, Clemons M, Joshua AM, Broom R. Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol. 2010;2(2):75\u201383.","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"1531_CR5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1593\/neo.06172","volume":"8","author":"CH Baker","year":"2006","unstructured":"Baker CH, Pino MS, Fidler IJ. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors. Neoplasia. 2006;8(6):470\u20136.","journal-title":"Neoplasia"},{"issue":"20","key":"1531_CR6","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1200\/JCO.2009.21.8461","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Molina AM. Targeting renal cell carcinoma. J Clin Oncol. 2009;27(20):3274\u20136.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1531_CR7","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.3747\/co.v16i0.407","volume":"16","author":"DY Heng","year":"2009","unstructured":"Heng DY, Kollmannsberger C. State-of-the-art treatment of metastatic renal cell carcinoma. Curr Oncol. 2009;16 Suppl 1:S16\u201323.","journal-title":"Curr Oncol"},{"issue":"1","key":"1531_CR8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cncr.21952","volume":"107","author":"AS Parker","year":"2006","unstructured":"Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, et al. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer. 2006;107(1):37\u201345.","journal-title":"Cancer"},{"issue":"6","key":"1531_CR9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/14712598.8.6.779","volume":"8","author":"EC Pfaffenroth","year":"2008","unstructured":"Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther. 2008;8(6):779\u201390.","journal-title":"Expert Opin Biol Ther"},{"issue":"25","key":"1531_CR10","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ Vijver van de","year":"2002","unstructured":"van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999\u20132009.","journal-title":"N Engl J Med"},{"key":"1531_CR11","first-page":"25","volume":"25","author":"G Leva Di","year":"2013","unstructured":"Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2013;25:25.","journal-title":"Annu Rev Pathol"},{"issue":"7","key":"1531_CR12","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/bjs.6628","volume":"96","author":"MI Aslam","year":"2009","unstructured":"Aslam MI, Taylor K, Pringle JH, Jameson JS. MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg. 2009;96(7):702\u201310.","journal-title":"Br J Surg"},{"issue":"3","key":"1531_CR13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ceb.2009.03.002","volume":"21","author":"M Negrini","year":"2009","unstructured":"Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer\u2014new paradigms in molecular oncology. Curr Opin Cell Biol. 2009;21(3):470\u20139.","journal-title":"Curr Opin Cell Biol"},{"issue":"5","key":"1531_CR14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2217\/pgs.10.26","volume":"11","author":"N Shomron","year":"2010","unstructured":"Shomron N. MicroRNAs and pharmacogenomics. Pharmacogenomics. 2010;11(5):629\u201332.","journal-title":"Pharmacogenomics"},{"issue":"Suppl","key":"1531_CR15","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ng1803","volume":"38","author":"E Hornstein","year":"2006","unstructured":"Hornstein E, Shomron N. Canalization of development by microRNAs. Nat Genet. 2006;38(Suppl):S20\u20134.","journal-title":"Nat Genet"},{"issue":"10","key":"1531_CR16","doi-asserted-by":"crossref","first-page":"e46566","DOI":"10.1371\/journal.pone.0046566","volume":"7","author":"D Shi","year":"2012","unstructured":"Shi D, Li P, Ma L, Zhong D, Chu H, Yan F, et al. A genetic variant in pre-miR-27a is associated with a reduced renal cell cancer risk in a Chinese population. PLoS One. 2012;7(10):e46566.","journal-title":"PLoS One"},{"issue":"8","key":"1531_CR17","doi-asserted-by":"crossref","first-page":"17085","DOI":"10.3390\/ijms140817085","volume":"14","author":"F Calore","year":"2013","unstructured":"Calore F, Lovat F, Garofalo M. Non-coding RNAs and cancer. Int J Mol Sci. 2013;14(8):17085\u2013110.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1531_CR18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361\u201387.","journal-title":"Stat Med"},{"issue":"4","key":"1531_CR19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cell.2009.02.011","volume":"136","author":"TA Cooper","year":"2009","unstructured":"Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell. 2009;136(4):777\u201393.","journal-title":"Cell"},{"issue":"286","key":"1531_CR20","first-page":"7","volume":"3","author":"AL Teixeira","year":"2012","unstructured":"Teixeira AL, Gomes M, Medeiros R. EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222. Front Genet. 2012;3(286):7.","journal-title":"Front Genet"},{"issue":"9","key":"1531_CR21","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.2215\/CJN.01170212","volume":"7","author":"JM Lorenzen","year":"2012","unstructured":"Lorenzen JM, Thum T. Circulating and urinary microRNAs in kidney disease. Clin J Am Soc Nephrol. 2012;7(9):1528\u201333.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1531_CR22","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3892\/ijo.2012.1647","volume":"41","author":"A Allegra","year":"2012","unstructured":"Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41(6):1897\u2013912.","journal-title":"Int J Oncol"},{"issue":"3","key":"1531_CR23","first-page":"178","volume":"32","author":"L Xu","year":"2011","unstructured":"Xu L, Liang YN, Luo XQ, Liu XD, Guo HX. Association of miRNAs expression profiles with prognosis and relapse in childhood acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2011;32(3):178\u201381.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"1531_CR24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.eururo.2011.01.044","volume":"59","author":"JWF Catto","year":"2011","unstructured":"Catto JWF, Alcaraz A, Bjartell AS, de Vere WR, Evans CP, Fussel S, et al. MicroRNA in prostate, bladder and kidney cancer: a systematic review. Eur Urol. 2011;59:671\u201381.","journal-title":"Eur Urol"},{"issue":"8","key":"1531_CR25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/gm272","volume":"3","author":"MY Shah","year":"2011","unstructured":"Shah MY, Calin GA. MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Med. 2011;3(8):56.","journal-title":"Genome Med"},{"key":"1531_CR26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1479-5876-10-119","volume":"10","author":"C Zhang","year":"2012","unstructured":"Zhang C, Zhang J, Hao J, Shi Z, Wang Y, Han L, et al. High level of miR-221\/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med. 2012;10:119.","journal-title":"J Transl Med"},{"issue":"16","key":"1531_CR27","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1158\/1078-0432.CCR-09-0092","volume":"15","author":"L Gramantieri","year":"2009","unstructured":"Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res. 2009;15(16):5073\u201381.","journal-title":"Clin Cancer Res"},{"key":"1531_CR28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1471-2407-10-367","volume":"10","author":"Z Chun-Zhi","year":"2010","unstructured":"Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010;10:367.","journal-title":"BMC Cancer"},{"issue":"5","key":"1531_CR29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00428-008-0676-8","volume":"453","author":"C Cinti","year":"2008","unstructured":"Cinti C, Vindigni C, Zamparelli A, La Sala D, Epistolato MC, Marrelli D, et al. Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch. 2008;453(5):449\u201355.","journal-title":"Virchows Arch"},{"issue":"55","key":"1531_CR30","first-page":"1479","volume":"10","author":"M Redova","year":"2012","unstructured":"Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10(55):1479\u20135876.","journal-title":"J Transl Med"},{"issue":"4","key":"1531_CR31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.canep.2012.04.001","volume":"36","author":"S Hauser","year":"2012","unstructured":"Hauser S, Wulfken LM, Holdenrieder S, Moritz R, Ohlmann CH, Jung V, et al. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol. 2012;36(4):391\u20134.","journal-title":"Cancer Epidemiol"},{"issue":"14","key":"1531_CR32","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2217\/pgs.13.184","volume":"14","author":"F Dias","year":"2013","unstructured":"Dias F, Teixeira AL, Santos JI, Gomes M, Nogueira A, Assis J, et al. Renal cell carcinoma development and miRNAs: a possible link to the EGFR pathway. Pharmacogenomics. 2013;14(14):1793\u2013803.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"1531_CR33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3892\/ijo.2013.2169","volume":"44","author":"H Iwamoto","year":"2014","unstructured":"Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 2014;44(1):53\u20138.","journal-title":"Int J Oncol"},{"issue":"1","key":"1531_CR34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yexmp.2012.10.005","volume":"94","author":"A Zhao","year":"2013","unstructured":"Zhao A, Li G, Peoc'h M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013;94(1):115\u201320.","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"1531_CR35","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1677\/ERC-09-0172","volume":"17","author":"V Coppola","year":"2010","unstructured":"Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. Endocr Relat Cancer. 2010;17(1):F1\u201317. doi:ERC-09-0172.","journal-title":"Endocr Relat Cancer"},{"key":"1531_CR36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1479-5876-10-55","volume":"10","author":"M Redova","year":"2012","unstructured":"Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10:55.","journal-title":"J Transl Med"},{"issue":"5","key":"1531_CR37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.eururo.2011.01.004","volume":"59","author":"YM Youssef","year":"2011","unstructured":"Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol. 2011;59(5):721\u201330.","journal-title":"Eur Urol"},{"issue":"9","key":"1531_CR38","doi-asserted-by":"crossref","first-page":"e25787","DOI":"10.1371\/journal.pone.0025787","volume":"6","author":"LM Wulfken","year":"2011","unstructured":"Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One. 2011;6(9):e25787.","journal-title":"PLoS One"},{"issue":"9","key":"1531_CR39","doi-asserted-by":"crossref","first-page":"e23936","DOI":"10.1371\/journal.pone.0023936","volume":"6","author":"L Zhou","year":"2011","unstructured":"Zhou L, Yang H. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR. PLoS One. 2011;6(9):e23936.","journal-title":"PLoS One"},{"issue":"4","key":"1531_CR40","first-page":"1387","volume":"98","author":"N Paulsen de","year":"2001","unstructured":"de Paulsen N, Brychzy A, Fournier MC, Klausner RD, Gnarra JR, Pause A, et al. Role of transforming growth factor-alpha in von Hippel\u2013Lindau (VHL)(\u2212\/\u2212) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A. 2001;98(4):1387\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"32","key":"1531_CR41","doi-asserted-by":"crossref","first-page":"13092","DOI":"10.1073\/pnas.0702387104","volume":"104","author":"A Franovic","year":"2007","unstructured":"Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, Lee S. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci U S A. 2007;104(32):13092\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1531_CR42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/gm272","volume":"3","author":"M Shah","year":"2011","unstructured":"Shah M, Calin G. MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Medicine. 2011;3(8):56.","journal-title":"Genome Medicine"},{"issue":"10","key":"1531_CR43","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/j.1440-1746.2010.06417.x","volume":"25","author":"XX Pu","year":"2010","unstructured":"Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25(10):1674\u201380.","journal-title":"J Gastroenterol Hepatol"},{"issue":"17","key":"1531_CR44","doi-asserted-by":"crossref","first-page":"13952","DOI":"10.1074\/jbc.M111.321646","volume":"287","author":"PK Santhekadur","year":"2012","unstructured":"Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, et al. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB and miR-221. J Biol Chem. 2012;287(17):13952\u20138.","journal-title":"J Biol Chem"},{"issue":"10","key":"1531_CR45","first-page":"11","volume":"128735","author":"Y Sun","year":"2013","unstructured":"Sun Y, Yu S, Liu Y, Wang F, Xiao H. Expression of miRNAs in papillary thyroid carcinomas is associated with BRAF mutation and clinicopathological features in Chinese patients. Int J Endocrinol. 2013;128735(10):11.","journal-title":"Int J Endocrinol"},{"issue":"5","key":"1531_CR46","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7150\/jca.6394","volume":"4","author":"BA Walter","year":"2013","unstructured":"Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA profiling of prostate cancer. J Cancer. 2013;4(5):350\u20137.","journal-title":"J Cancer"},{"issue":"7","key":"1531_CR47","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1600-0714.2010.01005.x","volume":"40","author":"CJ Yang","year":"2011","unstructured":"Yang CJ, Shen WG, Liu CJ, Chen YW, Lu HH, Tsai MM, et al. miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. J Oral Pathol Med. 2011;40(7):560\u20136.","journal-title":"J Oral Pathol Med"},{"issue":"3","key":"1531_CR48","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/sj.onc.1207162","volume":"23","author":"H Zhao","year":"2004","unstructured":"Zhao H, Dupont J, Yakar S, Karas M, LeRoith D. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene. 2004;23(3):786\u201394.","journal-title":"Oncogene"},{"issue":"5","key":"1531_CR49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1442-2050.2007.00786.x","volume":"21","author":"H Ge","year":"2008","unstructured":"Ge H, Cao YY, Chen LQ, Wang YM, Chen ZF, Wen DG, et al. PTEN polymorphisms and the risk of esophageal carcinoma and gastric cardiac carcinoma in a high incidence region of China. Dis Esophagus. 2008;21(5):409\u201315.","journal-title":"Dis Esophagus"},{"issue":"6","key":"1531_CR50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.cgt.7701050","volume":"14","author":"G Pappas","year":"2007","unstructured":"Pappas G, Zumstein LA, Munshi A, Hobbs M, Meyn RE. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther. 2007;14(6):543\u20139.","journal-title":"Cancer Gene Ther"},{"issue":"11","key":"1531_CR51","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.biocel.2013.09.003","volume":"45","author":"Y Liu","year":"2013","unstructured":"Liu Y, Cui H, Wang W, Li L, Wang Z, Yang S, et al. Construction of circular miRNA sponges targeting miR-21 or miR-221 and demonstration of their excellent anticancer effects on malignant melanoma cells. Int J Biochem Cell Biol. 2013;45(11):2643\u201350.","journal-title":"Int J Biochem Cell Biol"},{"issue":"9","key":"1531_CR52","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/onc.2010.487","volume":"30","author":"X Rao","year":"2011","unstructured":"Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, et al. MicroRNA-221\/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011;30(9):1082\u201397.","journal-title":"Oncogene"},{"issue":"44","key":"1531_CR53","doi-asserted-by":"crossref","first-page":"29897","DOI":"10.1074\/jbc.M804612200","volume":"283","author":"TE Miller","year":"2008","unstructured":"Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. MicroRNA-221\/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283(44):29897\u2013903.","journal-title":"J Biol Chem"},{"issue":"15","key":"1531_CR54","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1038\/sj.emboj.7601790","volume":"26","author":"C Sage le","year":"2007","unstructured":"le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. Regulation of the p27 (Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007;26(15):3699\u2013708.","journal-title":"EMBO J"},{"key":"1531_CR55","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.ejca.2008.04.014","volume":"44","author":"KK Abben","year":"2008","unstructured":"Abben KK, Luth TH, Janssen-Heijnen ML. No improvement in renal cell carcinoma survival: a population-based study in the Netherlands. Eur J Cancer. 2008;44:1701\u20139.","journal-title":"Eur J Cancer"},{"key":"1531_CR56","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ejca.2011.06.030","volume":"48","author":"K Kawakami","year":"2012","unstructured":"Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer. 2012;48:827\u201336.","journal-title":"Eur J Cancer"},{"key":"1531_CR57","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ctrv.2007.12.008","volume":"34","author":"D Furniss","year":"2008","unstructured":"Furniss D, Harnden P, Ali N, Royston P, Eisen T, Oliver RT, et al. Prognostic factors for renal cell carcinoma. Cancer Treat Rev. 2008;34:407\u201326.","journal-title":"Cancer Treat Rev"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-013-1531-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-013-1531-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-013-1531-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T02:16:20Z","timestamp":1647828980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-013-1531-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,31]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["1531"],"URL":"https:\/\/doi.org\/10.1007\/s13277-013-1531-3","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,31]]}}}